- Cellular Effects of Troglitazone on YD15 Tongue Carcinoma Cells
-
Ta Thi L, Yoo H
- KMID: 2354198
- Int J Oral Biol.
- 2016 Sep;41(3):113-118.
- doi: 10.11620/IJOB.2016.41.3.113
An FDA approved drug for the treatment of type II diabetes, Troglitazone (TRO), a peroxisome proliferator–activated receptor gamma agonist, is withdrawn due to severe idiosyncratic hepatotoxicity. In the search for... -
- CITED
-
- Close
- SHARE
-
- Close
